AperçuGraphiqueActualitésTraderScreen

HSBC Knock-Out MorphoSys AG/  DE000HS4GD98  /

Frankfurt Zert./HSBC
15/10/2024  14:00:53 Chg.0.000 Bid15/10/2024 Demandez à15/10/2024 Sous-jacent Prix d'exercice Date d'expiration Type d'option
3.040EUR 0.00% -
Bid taille: -		 -
Ask la taille: -		 MOR 37.9848 - 31/12/2078 Call
GlobeNewswire 16/07 SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of M...
TeleTrader 11/04 Novartis launches offer for Morphosys at €68 per share
TeleTrader 12/03 Germany clears Novartis' MorphoSys $2.9B deal
TeleTrader 05/02 Novartis to acquire MorphoSys for $2.9B
GlobeNewswire 11/08/2021 Royalty Pharma Reports Second Quarter 2021 Results
GlobeNewswire 03/06/2021 CONSTELLATION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of CNST and Encourages Investors ...
GlobeNewswire 02/06/2021 Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys
GlobeNewswire 27/04/2020 I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Mu...
GlobeNewswire 28/10/2019 MOR106 clinical development in atopic dermatitis stopped for futility
GlobeNewswire 23/04/2019 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire 23/04/2019 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire 31/01/2019 Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
GlobeNewswire 13/09/2018 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire 13/09/2018 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire 12/09/2018 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire 12/09/2018 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire 19/07/2018 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire 19/07/2018 Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atop...
GlobeNewswire 19/07/2018 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire 01/05/2018 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire 01/05/2018 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire 19/04/2018 Nasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock Market
GlobeNewswire 17/02/2018 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...
GlobeNewswire 17/02/2018 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...
GlobeNewswire 27/09/2017 Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...